EMB Corporation (EMBI)

[HoanTuong]

Is this too late to buy this stock?

[Dutchpaul1]

This stock you can go long

[PepsiMan]

Grabbed a starter on $EMBI this morning. Nice to see it's rocking. Looking good.


A nice Golden Cross is coming into view just ahead on the charts.



$EMBI


PEPSI

[Dutchpaul1]

EMBI - Emerald Bioscience Inc Forecast - CNNMoney.com

[Dutchpaul1]

Yahoo Finance...look EMBI
1y Target Est 2.48

[IHuser]

Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids
10:17 pm ET December 4, 2020 (Benzinga) Print
The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as the pharmaceutical sector and its investors.

That is according to Punit Dhillon, the recently appointed CEO at Emerald Bioscience Inc (OTC: EMBI), a San Diego-based biotech focused on cannabinoid-derived therapies for a spectrum of diseases with unmet medical needs. Through his various leadership roles at biopharmaceutical companies like OncoSec Medical Inc (NASDAQ: ONCS) and Inovio Pharmaceuticals Inc (NASDAQ: INO), Dhillon learned first-hand what it takes for biotech businesses to catalyze growth and provide well-differentiated approaches for the treatment of diseases.

Dhillon spoke with Benzinga about Emerald's proprietary technology which substantially enhances the local delivery, bioavailability, dosing, and – most importantly – potentially advantageous therapeutic effects of cannabinoids for diseases like glaucoma.

A First In Medicine: THC and CBD – the two major cannabinoids which act on specific receptors found on the endocannabinoid system – have been shown to maintain homeostasis in the body. Emerald’s research and development has further pushed the boundaries, bringing new ways to effect change on the endocannabinoid’s signalling pathways that involve a whole range of different physiological and pathological conditions.

“The endocannabinoid system is becoming increasingly recognized as an important system in the body that can be pharmacologically targeted for therapeutic benefits related to a myriad of diseases involving inflammation, pain, neurodegeneration, and immune modulation, to name a few."

Since Dhillon’s arrival, the firm has clarified a development path for its lead molecule.

"We're focusing our initial efforts on ocular opportunities, where there's been very little innovation, broadly speaking," the CEO said in reference to Emerald's clinical study of cannabis-infused treatments for glaucoma, the increase in intraocular pressure (IOP) that damages the retinal ganglion cells connected to the optic nerve, and causes irreversible loss of vision.

Using THC as medicine alone does have drawbacks, however. Specifically, THC is not concentrated enough to lower IOP. Additionally, the appearance of being under the influence and persistently low blood pressure are two other key detractors.

Emerald’s active pharmaceutical ingredients (API) overcome these common issues by enabling local delivery of more hydrophilic, comparatively minuscule THC doses directly to the eye, as an eyedrop. The drug's solubility offers deeper penetration into the eye where the THC conversion then delivers the molecule to the specific organ that regulates IOP.

“In our planned clinical study in humans, we are in fact going to have the benefit of using an agent that has already shown utility in humans – but our version has the basis to be very safe and far more effective."

“By controlling IOP, we can slow and preserve vision loss,” the CEO added. “Our mechanism is very unique compared to what exists. We’ve been able to deliver this and have an improvement over standard drugs.”

One Big Thing: There is a large subset of patients in the world who develop vision loss even while having controlled or normal IOP levels.

“The exact reason why these patients still suffer damage to their optic nerve and vision loss is not completely understood, but neurodegeneration is evident. Existing drugs offer no benefit for these patients," said Dhillon.

This area, according to the CEO, is where Emerald may inflict game-changing results.

“There is significant peer-reviewed literature to support the ability of cannabinoids, specifically THC, to provide neuroprotection of these cells that make up the optic nerve. There is nothing currently in the market that provides this neuroprotective benefit, making our mechanism very unique compared to what exists."

Path To Viability: Presently, Emerald’s work alongside a university that has a long-standing relationship at the federal level has given it a leg up in securing compelling proprietary technology.

"The University of Mississippi was given the first and only federal license to grow and conduct research on cannabis by the DEA going back 50 years. Their research produced the THCVHS and CBDVHS molecules that Emerald subsequently licensed from them," Dhillon said in reference to Emerald's fast-paced research and development.

Emerald’s products won’t be found at the storefront cannabis shop. Instead, the firm applies the full knowledge and capability of decades of R&D, clinical, and business development experience in the life sciences industry to advance differentiated, patented molecules through regulated processes, to validate their medical capabilities fully.

“The wider the "moat" of strong intellectual property and the stronger the data generated in well-designed clinical studies, the greater the potential interest a company with new medicines can generate from professional biotech investors and prospective pharmaceutical partners.”

Growth Prospects: Going forward, Emerald will look to do more preclinical assessments comparing its lead THCVHS compound to existing commercialized glaucoma drugs over their ability to reduce IOP and provide neuroprotection of the optic nerve.

If the firm can demonstrate superior IOP lowering and neuroprotection, then it's painting a new precedent for the treatment of glaucoma and potentially other diseases.

"We aim to start our first human study in the third quarter of 2021,” Dhillon added.

“Because of the nature of this disease – our monitoring period for each patient will be measured in just weeks – the overall study will be fast and relatively low-cost, and the study is designed in a manner that will also provide an early indication of efficacy not normally available in typical phase 1 studies.”

On another note, Emerald is moving forward on a rebranding process to represent the change in leadership and reinvigorated focus to enter the clinic within the next nine months. As part of this initiative, there will be a change to the firm’s corporate name and trading symbol, which is expected to occur in January.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[IHuser]

News

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
8:30 am ET January 5, 2021 (Globe Newswire) Print
Emerald Bioscience, Inc. (OTCQB: EMBI) ("Emerald" or the "Company"), a biopharmaceutical company focused on developing differentiated, proprietary cannabinoid derived molecules to treat glaucoma and other diseases with significant unmet needs, announced today that Punit Dhillon, CEO, Emerald Bioscience will be presenting at the KCSA Cannabis Investor Conference on Thursday, January 7, 2021.

Presentation details are as follows:

Event: KCSA Cannabis Investor Conference

Presentation Date: Thursday, January 7, 2021

Presentation Time: 2:30 - 3:00 PM ET

This will be an interactive online event where investors are invited to ask the Company questions in real-time. If attendees

[IHuser]

News

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
8:30 am ET January 5, 2021 (Globe Newswire) Print
Emerald Bioscience, Inc. (OTCQB: EMBI) ("Emerald" or the "Company"), a biopharmaceutical company focused on developing differentiated, proprietary cannabinoid derived molecules to treat glaucoma and other diseases with significant unmet needs, announced today that Punit Dhillon, CEO, Emerald Bioscience will be presenting at the KCSA Cannabis Investor Conference on Thursday, January 7, 2021.

Presentation details are as follows:

Event: KCSA Cannabis Investor Conference

Presentation Date: Thursday, January 7, 2021

Presentation Time: 2:30 - 3:00 PM ET

This will be an interactive online event where investors are invited to ask the Company questions in real-time. If attendees

[IHuser]

Company Profile
Emerald Bioscience, Inc., formerly Nemus Bioscience, Inc., is a biopharmaceutical company. The Company is focused on the discovery, development and the commercialization of cannabinoid-based therapeutics through its partnership with the University of Mississippi (UM). The Company is focused primarily on the development of early-stage cannabinoid product candidates. The Company's product candidates include NB1111, NB2222 and NB3111. The Company’s NB1111, a prodrug of Tetrahydrocannabinol (THC), is the Company's lead ocular compound. Its NB2222 is a prototype ocular formulation of the Emerald Bioscience CBD analog. Its product candidate NB2222 has an eye drop emulsion for the potential treatment and management of several eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The NB3111 product candidate is in research stage for the indication of Methicillin-resistant Staphylococcus aureus (MRSA).

[CAPTDASH]

Where did you see the patent info?

I have done pretty good on EMBI the last two weeks. Waiting for the dip to hit it again.

[IHuser]

new shell...mj blindness eye surgery...patented...let's_get_rich..$1.00PT..EMBI

[CAPTDASH]

I hope so. I loaded up on it.

[HoanTuong]

Is this good to buy anyone !Merry Xmax & Feliz Navida. !LOL

[1plus1]

^^^^^^^^^^ 06 ON DECK ^^^^^^^^^^^^^ EMBI WEEEEEEEEEEEEEEE

[1plus1]

i see bunch of smacks going thru

[1plus1]

nice been holding for a while >> reason for my buy was insiders buying ..

[Dutchpaul1]

I had to buy way over the ask to get in. Looks like this is going to rise xtreme

[Dutchpaul1]

When you try to nuy, the ask doesnt give. Meaning...real price is higher. We are going uppppp

[Dutchpaul1]

maybe because cnn money

[1plus1]

why are we up ??

[Dutchpaul1]

and again added

[Dutchpaul1]

and again added

[Dutchpaul1]

added again

[Dutchpaul1]

took pos today

[Kroozer1]

Rock n roll embi

[Darkchief]

Can we have some buy volume now please

[BrophInvest]

This stock trades so weird...

[Golden Cross]

EMBI Now Pink Current
https://www.otcmarkets.com/stock/EMBI

[Darkchief]

waiting on it patiently for the correction

[2014shelby]

Anything new here? Seems like it’s just trading sideways at best

[Darkchief]

just pumping this stock

[Darkchief]

Is there anyone here ?

[Southern Gal]

Hindsight...

Where's the bottom?

[Joemarly]

Just got 30,000 shares at 0.0450
Ya just never know??!

[N.C.LUCKY(7)]

House to vote on marihuana rescheduling the week of September 21st... https://mjbizdaily.com/us-house-to-take-up-marijuana-descheduling-bill-week-of-sept-21/

[Vipyr]

Pretty large insider buying from the new CEO.

https://insider-analysis.com/search_transactions.php?ticker=TABLE_EMBI

[willlbone]

Buy at a nickle.

[newguy49]

a lot of movement the last few days, wonder what's going on?

[Vinpat]

Most of these companies have massive dilution. I’d take the IP here over any of the others in this OTC sector yet it has about the lowest valuation.

[willlbone]

Massive dilution.

[willlbone]

Volume drop.

[whytestocks]

News: $EMBI Emerald Bioscience Announces $2.0 Million Registered Direct Offering

Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced i...

Read the whole news EMBI - Emerald Bioscience Announces $2.0 Million Registered Direct Offering

[whytestocks]

News: $EMBI Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience's Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting

Long Beach, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Glauconix Bi...

Got this from EMBI - Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience's Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting

[newguy49]

well quite a day! 4 times average volume and up 27%. Don't see any news, I wonder what is up. Hope this continues!!

[newguy49]

A little news.
https://finance.yahoo.com/news/emerald-bioscience-secures-fields-licenses-120000981.html

[Shane96720]

I've been in it for awhile. I am banking on their work with University of Mississippi.
Which is one of 2 Universities that have been studying cannabis legally for decades. University of Louisiana is the other one.If my information is right.

[newguy49]

picked up some more shares today but judging by the activity on this board I must be the only share holder around.:^)

[Vector93]

Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

Mon, 01 Apr 2019 11:30 GMT | GlobeNewswire | Symbol: EMBI
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE –

Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that the Drug Enforcement Administration (DEA) has conducted a scientific review of the chemical structure of cannabidiol-­valine-hemisuccinate (CBDVHS) and determined that CBDVHS is not a regulated chemical nor controlled substance under the Controlled Substances Act.

“This is a welcomed finding by the DEA. Their decision may help us expand the network of clinical testing sites, permit a greater cross-section of patients to participate in studies of this drug, as well as speed the initiation of clinical trials,” said Brian Murphy, MD, CEO and Chief Medical Officer of Emerald Bioscience, Inc. “Emerald is planning to study this analog of CBD for potential use in managing diseases affecting the eye, particularly those that compromise the functioning of the optic nerve, leading to vision loss.”

About Emerald Bioscience, Inc.

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Emerald Bioscience is part of the Emerald Group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

For more information, visit www.emeraldbio.life

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered only to accredited investors pursuant to Regulation D of the Securities Act

[rocco_p_coletrain]

Damn, when this stock drops it's like a falling knife.

Lookout below !!

On watch.

[newguy49]

Vector93, pretty sure you are right, it has had a very good run. not surprising to see a pullback. some people are sure to take some profit.